首页> 美国卫生研究院文献>BMC Cancer >AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer

【2h】

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer

机译：atezotribe：单独或与atezolizumab单独或与atezolizumab组合的随机相二研究作为不可切种的转移性结直肠癌患者的初始治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Rationale for combining chemotherapy, bevazicumab and atezolizumab. DC, dendritic cell; ICD, immunogenic cell death; MDSCs, myeloid-derived suppressor cells; Tregs, regulatory T cells; VEGF: Vascular Endothelial Growth Factor

机译：结合化疗，Bevazicumab和Atezolizumab的理由。 DC，树突细胞; ICD，免疫原性细胞死亡; MDSCS，粒子源性抑制细胞; Tregs，监管T细胞; VEGF：血管内皮生长因子

著录项

期刊名称 BMC Cancer
作者
Carlotta Antoniotti; Beatrice Borelli; Daniele Rossini; Filippo Pietrantonio; Federica Morano; Lisa Salvatore; Sara Lonardi; Federica Marmorino; Stefano Tamberi; Salvatore Corallo; Giampaolo Tortora; Francesca Bergamo; Di Stefano Brunella; Alessandra Boccaccino; Elisa Grassi; Patrizia Racca; Emiliano Tamburini; Giuseppe Aprile; Roberto Moretto; Luca Boni; Alfredo Falcone; Chiara Cremolini;
展开▼
作者单位

展开▼
年(卷),期 2020(-1),-1
年度 2020
页码 -1
总页数 9
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

机译：Folfoxiri;转移性结直肠癌;免疫疗法;免疫检查点抑制剂;atezolizumab;化疗;三重胶质;贝伐单抗;微卫星状态;

相似文献

外文文献
中文文献
专利

1. AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer [J] . Carlotta Antoniotti, Beatrice Borelli, Daniele Rossini, BMC Cancer . 2020,第1期

机译：atezotribe：单独或与atezolizumab单独或与atezolizumab组合的随机相二研究，作为不可切种的转移性结直肠癌患者的初始治疗
2. Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial [J] . Cremolini Chiara, Malmorino Federica, Bergamo Francesca, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：第II期随机研究用Bevacizumab或Bevacizumab加上一流诱导叶昔昔昔单乳蛋白酶转移结直肠癌患者的牛伐单抗和贝伐单抗化疗研究：MOMA试验
3. Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients [J] . European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2017,第期

机译：用伊立替康/西替昔单抗的治疗序列，然后进行Folfox-4或转移性结肠直肠癌患者的反向策略，在第一线Folfiri / Bevacizumab后进展：用于研究胃肠癌期III的意大利组，随机试验比较两种治疗序列结肠直肠转移性患者
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. New Models of Colorectal Cancer to Facilitate Therapy Development for Metastatic Disease [D] . O'Rourke, Kevin. 2017

机译：新型结肠直肠癌促进转移性疾病治疗的疗效
6. TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer [O] . Beatrice Borelli, Roberto Moretto, Sara Lonardi, 2018

机译：TRIPLETE：改良的FOLFOXIRI加panitumumab与mFOLFOX6加panitumumab作为无法切除的RAS和BRAF野生型转移性结直肠癌患者的初始治疗的随机III期研究
7. 186P Bevacizumab in combination with 5-fluorouracil (5-FU) based doublet chemotherapy as neoadjuvant therapy for Chinese patients with previously untreated, unresectable liver-only metastatic colorectal cancer: A multi-center, single-arm phase II study [O] . D.-S. Wan, S.-Z. Zhang, Y.-Z. Chen, 2016

机译：186p Bevacizumab与5-氟尿嘧啶（5-FU）的双核化疗组合为新辅助治疗中国患者以前未经治疗的肝脏转移性结直肠癌：多中心，单臂期II研究

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer

摘要

著录项

相似文献

相关主题

期刊订阅